Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mallinckrodt PLC MNKTQ

Healthcare
Mallinckrodt plc develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and... see more

Recent & Breaking News (OTCPK:MNKTQ)

Mallinckrodt Announces Submission of 510(k) to the U.S. FDA for Inhaled Nitric Oxide Delivery System

PR Newswire September 28, 2022

Mallinckrodt Announces Appointment of Lisa French as Chief Commercial Officer

PR Newswire September 19, 2022

Mallinckrodt Receives U.S. FDA Approval for Terlivaz® (terlipressin) for injection for the Treatment of Hepatorenal Syndrome (HRS)

PR Newswire September 14, 2022

Mallinckrodt plc Provides Update on Executive Committee

PR Newswire August 17, 2022

Mallinckrodt Announces Appointment of Karen Ling to Its Board of Directors

PR Newswire August 17, 2022

Mallinckrodt plc Reports Second Quarter 2022 Financial Results and Provides 2022 Financial Guidance

PR Newswire August 11, 2022

MALLINCKRODT TO REPORT EARNINGS RESULTS FOR SECOND QUARTER 2022 AND PROVIDE BUSINESS UPDATE

PR Newswire August 3, 2022

Mallinckrodt to Present Data on Terlipressin in Adult Patients with Hepatorenal Syndrome (HRS) at the European Association for the Study of the Liver (EASL) 2022 International Liver Congress

PR Newswire June 23, 2022